Sildenafil oral spray - Aspargo Laboratories
Alternative Names: ASP-001; ASP-002; BANDOL; HEZKUELatest Information Update: 21 Aug 2025
At a glance
- Originator Farmalider
- Developer Aspargo Laboratories
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Erectile dysfunction
Most Recent Events
- 15 Aug 2025 Aspargo Laboratories plans a phase-I trial (In volunteers) in USA (PO), (NCT07117383)
- 15 Apr 2025 Phase-I clinical trials in Erectile dysfunction (In volunteers) in USA (Transmucosal) (NCT06872866)
- 15 Apr 2025 Launched for Erectile dysfunction in Germany (Transmucosal) before April 2025 (Aspargo Laboratories website, April 2025)